Current Therapy of Chronic Hepatitis C Virus in Treatment-Naive Patients

  • Alhareth AlJuboori
  • Satinder Kaur
  • Veysel TahanEmail author


Hepatitis C virus (HCV) is one of the most commonly transmitted blood-borne diseases in the United States and the world with a high percentage of infected individuals leading to persistent infection and progression of hepatic inflammation. Patients who fail to clear the virus spontaneously will develop chronic HCV, ultimately leading to the development of cirrhosis in 10–20% of patients over the following 2–3 decades. The goal of therapy is to prevent HCV-related complications with early detection and prevention to substantially impact the prognosis. Liver biopsy remains the gold standard for staging fibrosis but, with recent advances in noninvasive methods, serum biomarkers and imaging techniques can be utilized first to avoid complications from biopsy. Given recent advances in treatment options with direct-acting antivirals (DAAs), data shows increased SVR rates, along with simpler regimens and less severe side effect profiles.


Hepatitis C virus Direct-acting antivirals Sustained virological response Cirrhosis FibroScan 



Disclosure: Nothing to disclose.


  1. 1.
    Jimmerson LC. The clinical pharmacology of ribavirin: intracellular effects on endogenous nucleotides and hemolytic anemia. Boulder: University of Colorado Boulder; 2010.Google Scholar
  2. 2.
    Denniston M, Jiles R, Drobeniuc J, Klevens R, Ward J, McQuillan G, Holmberg S. Chronic hepatitis C virus infection in the United States, National Health and nutrition examination survey 2003 to 2010. Ann Intern Med. 2014;160:293–300.CrossRefGoogle Scholar
  3. 3.
    Cox A. Global control of hepatitis C virus. Science. 2015;349:790–1.CrossRefGoogle Scholar
  4. 4.
    Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016;10:681–701.CrossRefGoogle Scholar
  5. 5.
    Chen S, Morgan T. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:47–52.CrossRefGoogle Scholar
  6. 6.
    Kish T, Aziz A, Sorio M. Hepatitis C in a new era: a review of current therapies. Pharm Ther. 2017;42:316–29.Google Scholar
  7. 7.
    Initial treatment of HCV infection | HCV guidance. 2017. Accessed 29 Nov 2017.
  8. 8.
    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-a, non-B viral hepatitis genome. Science. 1989;244:359–62.CrossRefGoogle Scholar
  9. 9.
    Penin F, Dubuisson J, Rey F, Moradpour D, Pawlotsky J. Structural biology of hepatitis C virus. Hepatology. 2004;39:5–19.CrossRefGoogle Scholar
  10. 10.
    Tan S. Chapter 6: HCV NS3-4A Serine protease. In: Hepatitis C viruses. Wymondham: Horizon Bioscience; 2006.Google Scholar
  11. 11.
    Gosert R, Egger D, Lohmann V, et al. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol. 2003;77:5487–92.CrossRefGoogle Scholar
  12. 12.
    Chang K, Kyong C. Hepatitis C virus: virology and life cycle. Clin Mol Hepatol. 2013;19:17–25.CrossRefGoogle Scholar
  13. 13.
    Pawlotsky J, Brillet R, Penin F, et al. Does nonstructural 5A (NS5A) protein mediate HCV genotype 1 resistance to interferon (IFN) alpha-based therapy by antagonizing IFN antiviral effect? Hepatology. 2002;36:283A.CrossRefGoogle Scholar
  14. 14.
    Petruzziello A, Marigliano S, Loquercio G, et al. Hepatitis C virus (HCV) genotypes distribution: an epidemiological update in Europe. Infect Agents Cancer. 2016;11:53.CrossRefGoogle Scholar
  15. 15.
    Messina J, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2014;61:77–87.CrossRefGoogle Scholar
  16. 16.
    Core concepts—HCV epidemiology in the United States—Screening and diagnosis of hepatitis C infection—hepatitis C online. 2017. Accessed 1 Dec 2017.
  17. 17.
    Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat. 2009;16:75–90.CrossRefGoogle Scholar
  18. 18.
    Yu M, Dai C, Huang J, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. 2008;47:1884–93.CrossRefGoogle Scholar
  19. 19.
    Yu M, Dai C, Huang J, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007;56:553–5.CrossRefGoogle Scholar
  20. 20.
    Hayes C, Chayama K. Emerging treatments for chronic hepatitis C. J Formos Med Assoc. 2015;114:204–15.CrossRefGoogle Scholar
  21. 21.
    Jacobson I, McHutchison J, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.CrossRefGoogle Scholar
  22. 22.
    Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with Peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146:1669–79.CrossRefGoogle Scholar
  23. 23.
    Pawlotsky J. NS5A inhibitors in the treatment of hepatitis C. J Hepatol. 2013;59:375–82.CrossRefGoogle Scholar
  24. 24.
    Hézode C, Hirschfield G, Ghesquiere W, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2014;64:948–56.CrossRefGoogle Scholar
  25. 25.
    Cacoub P. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016;3:3–14.PubMedPubMedCentralGoogle Scholar
  26. 26.
    European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511.Google Scholar
  27. 27.
    Afdhal N, Bacon B, Patel K, et al. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol. 2015;13:772–9.CrossRefGoogle Scholar
  28. 28.
    Motola D, Caravan P, Chung R, Fuchs B. Noninvasive biomarkers of liver fibrosis: clinical applications and future directions. Curr Pathobiol Rep. 2014;2:245–56.CrossRefGoogle Scholar
  29. 29.
    Konerman M, Mehta S, Sutcliffe C, et al. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology. 2014;59:767–75.CrossRefGoogle Scholar
  30. 30.
    Zeuzem S, Mizokami M, Pianko S, et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol. 2017;66:910–8.CrossRefGoogle Scholar
  31. 31.
    Zeuzem S, Ghalib R, Reddy K, et al. Grazoprevir–Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 Infection: A randomized TrialC-EDGE treatment-naive trial of Grazoprevir–Elbasvir. Ann Intern Med. 2015;163:1–3.CrossRefGoogle Scholar
  32. 32.
    Kwo P, Gane E, Peng C, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017;152:164–75.CrossRefGoogle Scholar
  33. 33.
    Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1087–97.CrossRefGoogle Scholar
  34. 34.
    Kwo P, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. J Hepatol. 2017;67:263–71.CrossRefGoogle Scholar
  35. 35.
    Poordad F, Felizarta F, Asatryan A, et al. 98%–100% SVR4 in HCV genotype 1 non-cirrhotic treatment-Naïve or pegylated interferon/ribavirin null responders with the combination of the next generation NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 (SURVEYOR-1). AASLD Abs.41; 2015.Google Scholar
  36. 36.
    Zeuzem S, Feld J, Wang S, et al. ENDURANCE-1: efficacy and safety of 8-versus 12-week treatment with ABT-493/ABT-530 in patients with chronic HCV genotype 1 infection. Hepatology. 2016;64:132A–3A.Google Scholar
  37. 37.
    Forns X, Lee S, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17:1062–8.CrossRefGoogle Scholar
  38. 38.
    Atsukawa M, Chayama K, Suzuki F, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients infected with HCV GT1–3 by renal impairment status: a pooled analysis of two phase 3 Japanese trials. Hepatology. 2017;66:634A–5A.Google Scholar
  39. 39.
    Feld J, Jacobson I, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599–607.CrossRefGoogle Scholar
  40. 40.
    Jacobson I, Asselah T, Nahass R, et al. A randomized phase 3 trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 weeks compared to Sofosbuvir/Velpatasvir for 12 weeks in DAA-naive genotype 1–6 HCV infected patients: the POLARIS-2 study. Hepatology. 2016;64(Suppl 1):1126A.Google Scholar
  41. 41.
    Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98.CrossRefGoogle Scholar
  42. 42.
    Kowdley K, Gordon S, Reddy K, et al. Ledipasvir and Sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–88.CrossRefGoogle Scholar
  43. 43.
    Kwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 2016;64:370–80.CrossRefGoogle Scholar
  44. 44.
    Wyles D, Ruane P, Sulkowski M, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714–25.CrossRefGoogle Scholar
  45. 45.
    Feld J, Kowdley K, Coakley E, et al. Treatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–603.CrossRefGoogle Scholar
  46. 46.
    Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r–ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–92.CrossRefGoogle Scholar
  47. 47.
    Poordad F, Hezode C, Trinh R, et al. ABT-450/r–ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–82.CrossRefGoogle Scholar
  48. 48.
    Kowdley K, Colombo M, Zadeikis N, et al. ENDURANCE-2: safety and efficacy of ABT-493/ABT-530 in hepatitis C virus genotype 2-infected patients without cirrhosis, a randomized, double-blind, placebo-controlled study. Hepatology. 2016;63:39A.Google Scholar
  49. 49.
    Hassanein T, Wyles D, Wang S, et al. SURVEYOR-II, part 4: glecaprevir/pibrentasvir demonstrates high SVR rates in patients with HCV genotype 2, 4, 5, or 6 infection without cirrhosis following an 8-week treatment duration. In Vitro. 2016;11:2–3.Google Scholar
  50. 50.
    Foster G, Afdhal N, Roberts S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–17.CrossRefGoogle Scholar
  51. 51.
    Sulkowski M, Gardiner D, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–21.CrossRefGoogle Scholar
  52. 52.
    Foster G, Gane E, Asatryan A, et al. ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis. J Hepatol. 2017;66:S33.CrossRefGoogle Scholar
  53. 53.
    Foster G, Thompson A, Ruane P, et al. A randomized phase 3 trial of sofosbuvir/velpatasvir/voxilaprevir for 8 weeks and sofosbuvir/velpatasvir for 12 weeks for patients with genotype 3 HCV infection and cirrhosis: the POLARIS-3 study. Hepatology. 2016;63:135A–6A.Google Scholar
  54. 54.
    Nelson D, Cooper J, Lalezari J, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127–35.CrossRefGoogle Scholar
  55. 55.
    Hézode C, Lebray P, De Ledinghen V, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. Liver Int. 2017;37:1314–24.CrossRefGoogle Scholar
  56. 56.
    Asselah T, Hezode C, Zadeikis N, et al. Endurance-4: efficacy and safety of ABT-493/ABT-530 treatment in patients with chronic HCV genotype 4, 5 or 6 infection. AASLD liver meeting 2016 Abstract 73; 2016.
  57. 57.
    Asselah T, Reesink H, Gerstoft J, et al. High efficacy of elbasvir and grazoprevir with or without ribavirin in 103 treatment-naive and experienced patients with HCV genotype 4 infection: a pooled analysis AASLD liver meeting 2016 Abstract 251; 2016.Google Scholar
  58. 58.
    Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis. 2015;15:1049–54.CrossRefGoogle Scholar
  59. 59.
    Abergel A, Asselah T, Metivier S, et al. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis. 2016;16:459–64.CrossRefGoogle Scholar
  60. 60.
    Hézode C, Asselah T, Reddy K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502–9.CrossRefGoogle Scholar
  61. 61.
    Asselah T, Hassanein T, Qaqish R, et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis (AGATE-I). Hepatology. 2015;62:563A–4A.Google Scholar
  62. 62.
    Gane E, Hyland R, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology. 2015;149:1454–61.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Alhareth AlJuboori
    • 1
  • Satinder Kaur
    • 2
  • Veysel Tahan
    • 1
    Email author
  1. 1.Department of Internal Medicine, Division of Gastroenterology and HepatologyUniversity of Missouri School of MedicineColumbiaUSA
  2. 2.Department of Internal Medicine, VA Sierra Nevada Health Care SystemUniversity of Nevada School of MedicineRenoUSA

Personalised recommendations